PRC
APLS

Pearl River Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Pearl River Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,259
Closed -$250K – 425
2024
Q1 		$250K Buy
+4,259
New +$271K 0.04% 417
2023
Q1 		– Sell
-4,208
Closed -$218K – 488
2022
Q4 		$218K Buy
4,208
+297
+8% +$15.8K 0.04% 465
2022
Q3 		$267K Buy
+3,911
New +$231K 0.05% 392

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pearl River Capital's APLS Position: Q2 2024 in Review

Pearl River Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 4,259 shares — an estimated $250K sold.

Pearl River Capital first reported a position in APLS in Q3 2022 and held it in 3 quarters. The position peaked at $267K in Q3 2022. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Pearl River Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Pearl River Capital sold 4,259 Apellis Pharmaceuticals shares in Q2 2024, an estimated $250K.
  • Pearl River Capital first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Pearl River Capital's Apellis Pharmaceuticals position peaked at $267K in Q3 2022.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.